Safety and PK of Multiple Ascending Doses of WCK 2349 in Healthy Volunteers

Phase 1, randomised, double-blind trial in acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CAP) and hospital-acquired bacterial pneumonia (HAP) comparing WCK 2349 with Placebo (2 arms). Primary endpoints: Safety and Tolerability of multiple doses of WCK 2349 at 12 days and Pharmacokinetics of multiple doses of WCK 2349 at 5 days. Started Mar 2011; status: completed.